Figure 2.

FG Treatment Improves TME

(A) IF images of CD31-stained (red) sections of LLC tumors. Scale bar, 100 μm.

(B) Quantification of vessel density and vessel lumen area in LLC tumors (n = 6).

(C) IF images of ZO-1 (green) and CD31 (red)-stained sections of LLC tumors. Scale bar, 50 μm.

(D) Quantification of the ZO-1⁺ area ratio in the CD31⁺ area (n = 5).

(E) IF images of NG2 (green) and CD31 (red)-stained sections of LLC tumors. Scale bar, 50 μm.

(F) Quantification of the NG2⁺ area ratio in the CD31⁺ area (n = 5).

(G) Images of blood perfusion (low-power field; scale bar, 1 mm) and blood leakage (high-power field; scale bar, 100 μm) in LLC tumor tissues using FITC-conjugated dextran.

(H and I) IF images and quantification of the tumor hypoxic region by anti-pimonidazole staining in LLC tumors (anti-CD31 antibody, red; anti-pimonidazole antibody, green; n = 6). Arrowheads indicate pimonidazole-positive area. Scale bar, 100 μm.

Data represent means ±SEM; Mann-Whitney test (B, D, F, and I). **p < 0.01. See also Figure S2.